Progenics Pharmaceuticals, Inc. (PGNX) in Focus: Stock Rises 8.5% – Tale of the Tape

Zacks
Progenics Pharmaceuticals, Inc. (PGNX) was a big mover last session, as the company saw its shares rise over 8% on the day. This rally higher can be attributable to solid volume too with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $4.14 to $4.67 in the past one-month time frame, showed a pick-up yesterday at $4.60.

In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged. However, yesterday’s price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Progenics Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other attractive players in the healthcare industry include Mallinckrodt plc (MNK), carrying a Zacks Rank #1 (Strong Buy) along with Akorn, Inc. (AKRX) and Dr. Reddy's Laboratories Ltd. (RDY) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply